Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion by W., Toller et al.
  	

Preoperative and perioperative use of levosimendan in cardiac surgery:
European expert opinion
W. Toller, M. Heringlake, F. Guarracino, L. Algotsson, J. Alvarez, H.
Argyriadou, T. Ben-Gal, V. ˇCerny´, B. Cholley, A. Eremenko, J.L. Guerrero-
Orriach, K. Ja¨rvela¨, N. Karanovic, M. Kivikko, P. Lahtinen, V. Lomivorotov,
R.H. Mehta, ˇS. Musˇicˇ, P. Pollesello, S. Rex, H. Riha, A. Rudiger, M. Salmen-
pera¨, L. Szudi, L. Tritapepe, D. Wyncoll, A. ¨Owall
PII: S0167-5273(15)00149-7
DOI: doi: 10.1016/j.ijcard.2015.02.022
Reference: IJCA 19674
To appear in: International Journal of Cardiology
Received date: 12 August 2014
Revised date: 9 February 2015
Accepted date: 21 February 2015
Please cite this article as: Toller W, Heringlake M, Guarracino F, Algotsson L, Al-
varez J, Argyriadou H, Ben-Gal T, Cˇerny´ V, Cholley B, Eremenko A, Guerrero-Orriach
JL, Ja¨rvela¨ K, Karanovic N, Kivikko M, Lahtinen P, Lomivorotov V, Mehta RH,
Musˇicˇ Sˇ, Pollesello P, Rex S, Riha H, Rudiger A, Salmenpera¨ M, Szudi L, Tritapepe
L, Wyncoll D, O¨wall A, Preoperative and perioperative use of levosimendan in car-
diac surgery: European expert opinion, International Journal of Cardiology (2015), doi:
10.1016/j.ijcard.2015.02.022
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Preoperative and perioperative use of levosimendan in cardiac surgery: European 
expert opinion 
 
W. Toller
1
*, M. Heringlake
2
, F. Guarracino
3
, L. Algotsson
4
, J. Alvarez
5
, H. Argyriadou
6
, T. 
Ben-Gal
7
, V. Černý8, B. Cholley9, A. Eremenko10, J. L. Guerrero-Orriach11, K. Järvelä12, N. 
Karanovic
13
, M. Kivikko
14
, P. Lahtinen
15
, V. Lomivorotov
16
, R. H. Mehta
17
, Š. Mušič18, P. 
Pollesello
14
, S. Rex
19
, H. Riha
20
, A. Rudiger
21
, M. Salmenperä
22
, L. Szudi
23
, L. Tritapepe
24
, D. 
Wyncoll
25
, A. Öwall
26
 
 
1
Department of Anaesthesiology and Intensive Care Medicine, University Hospital of Graz, 
Graz, Austria; 
2
Department of Anaesthesiology, University of Lübeck, Lübeck, Germany; 
3
Department of Anaesthesia and Critical Care Medicine, Azienda Ospedialiero-Universitaria 
Pisana, Pisa, Italy; 
4
Department of Cardiothoracic Surgery, Skånes University Hospital Lund, 
Lund, Sweden; 
5
Department of Anaesthesiology and Intensive Care, University Hospital of 
Santiago de Compostela, Santiago de Compostela, Spain; 
6
Department of Anaesthesiology 
and Intensive Care Unit, Aristotle University of Thessaloniki, AHEPA Teaching Hospital, 
Thessaloniki, Greece; 
7
Heart Failure Unit, Rabin Medical Centre, Petach Tikva, Israel; 
8
Department of Anaesthesiology and Intensive Care, University Hospital Hradec Kralove, 
Hradec Kralove, Czech Republic; 
9
Department of Anaesthesiology and Intensive Care, 
Hôpital Européen Georges Pompidou, AP-HP, and Université Paris Descartes, Paris, France; 
10“B. V. Petrovsky” Russian National Centre of Surgery, Moscow, Russia; 11Department of 
Cardio-Anaesthesiology, University Hospital Virgen de la Victoria de Malaga, Malaga, 
Spain; 
12
Heart Centre and Intensive Care Unit, Tampere University Hospital, Tampere, 
Finland; 
13
Department of Anaesthesiology and Intensive Care, University Hospital Split, Split, 
Croatia; 
14
Orion Pharma, Critical Care, Espoo, Finland; 
15
Department of Anaesthesiology and 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Intensive Care, Kuopio University Hospital, Kuopio, Finland; 
16“E. N. Meshalkin” State 
Novosibirsk Research Institute of Circulation Pathology, Novosibirsk, Russia; 
17
Department 
of Internal Medicine and Cardiology, Duke University Medical Center and Duke Clinical 
Research Institute, Durham, NC, USA; 
18
Department of Cardio-Anaesthesiology, University 
Clinical Centre Ljubljana, Ljubljana, Slovenia; 
19
Department of Anaesthesiology, UZ Leuven, 
Campus Gasthuisberg, Leuven, Belgium; 
20
Cardiothoracic Anaesthesiology and Intensive 
Care, Department of Anaesthesiology and Intensive Care Medicine, Institute for Clinical and 
Experimental Medicine, Prague, Czech Republic; 
21
Institute of Anaesthesiology, University 
Hospital of Zürich, Zürich, Switzerland; 
22
Department of Anaesthesiology, Intensive Care, 
Emergency and Pain Medicine, Helsinki University Hospital, Helsinki, Finland; 
23
Department 
of Anaesthesiology and Intensive Care, Gottsegen György National Institute of Cardiology, 
Budapest, Hungary; 
24
Department of Anaesthesiology and Intensive Care, Policlinico 
“Umberto I”, “La Sapienza” University of Rome, Rome, Italy; 25Department of Critical Care, 
St. Thomas’ Hospital, London, UK; 26Department of Cardiothoracic Surgery, Karolinska 
University Hospital Solna, Stockholm, Sweden. 
 
Running title: Levosimendan in cardiac surgery 
 
*Corresponding author: Wolfgang Toller 
Department of Anaesthesiology and Intensive Care Medicine 
University Hospital of Graz 
Auenbruggerplatz 29 
8036 Graz, Austria 
E-mail: wolfgangtoller@gmail.com 
Tel: +43-316-38514663 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Abstract 
 
In cardiac surgery, postoperative low cardiac output has been shown to correlate with 
increased rates of organ failure and mortality. Catecholamines have been the standard therapy 
for many years, although they carry substantial risk for adverse cardiac and systemic effects, 
and have been reported to be associated with increased mortality. On the other hand, the 
calcium sensitiser and potassium channel opener levosimendan has been shown to improve 
cardiac function with no imbalance in oxygen consumption, and to have protective effects in 
other organs. Numerous clinical trials have indicated favourable cardiac and non-cardiac 
effects of preoperative and perioperative administration of levosimendan. A panel of 27 
experts from 18 countries has now reviewed the literature on the use of levosimendan in on-
pump and off-pump coronary artery bypass grafting and in heart valve surgery. This panel 
discussed the published evidence in these various settings, and agreed to vote on a set of 
questions related to the cardioprotective effects of levosimendan when administered 
preoperatively, with the purpose of reaching a consensus on which patients could benefit from 
the preoperative use of levosimendan and in which kind of procedures, and at which doses 
and timing should levosimendan be administered. Here, we present a systematic review of the 
literature to report on the completed and ongoing studies on levosimendan, including the 
newly commenced LEVO-CTS phase III study (NCT02025621), and on the consensus 
reached on the recommendations proposed for the use of preoperative levosimendan.  
 
Keywords: cardiac surgery; CABG; valve surgery; low cardiac output syndrome; inodilator; 
cardioprotective 
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1. Introduction 
 
In patients undergoing cardiac surgery, low cardiac output syndrome (LCOS) is a disastrous 
event that can result in life-threatening complications [1,2]. With LCOS, the mortality rate of 
these patients can be as high as 16.9% (versus 0.9% without LCOS) [2]. Preoperative reduced 
left ventricular function has been recognised as the main risk factor for LCOS [3,4]. 
Cardiac surgery is also usually accompanied by multi-faceted effects, which include 
sympathetic activation, inflammation, and haemodynamic changes, and is thus likely to 
promote organ dysfunction. Of note, acute kidney injury is frequently observed after cardiac 
surgery, and this is associated with increased long-term mortality after cardiothoracic surgery 
[5]. Postoperative acute kidney injury can be part of cardiorenal syndrome, which is a classic 
example of organ dysfunction that can arise due to hypoperfusion, which triggers a 
sympathoadrenergic response, hyperglycaemia and inflammation [6].  
Inotropic support is frequently initiated in the perioperative period to improve post-
bypass ventricular function. However, inotropes include the potential risk of increased 
myocardial oxygen consumption, which can result in cardiac ischaemia, with subsequent 
damage to hibernating but viable myocardium, and arrhythmias. This has prompted an 
ongoing debate on the potential harm associated with inotropic therapy in cardiac surgery. 
Indeed, the use of perioperative and postoperative inotropes has recently been found to be 
associated with increased mortality and major postoperative morbidity [7].  
Administration of the calcium sensitiser levosimendan, which has been approved for 
management of acutely decompensated heart failure, might offer a solution to this unmet need. 
The effects of levosimendan as an inodilator are based on a triple mechanism of action [8] 
that provides positive inotropy with a neutral effect on oxygen consumption [9], and with 
preconditioning [10], cardioprotective [11], anti-stunning [12] and anti-ischaemic effects [13]. 
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In a recent meta-analysis of clinical trials, Harrison and colleagues evaluated the effects of 
levosimendan in cardiac surgery patients with and without preoperative systolic dysfunction 
[14]. Here, they showed that mortality and other adverse outcomes, such as postoperative 
renal failure requiring dialysis, postoperative atrial fibrillation, and myocardial injury, were 
reduced with levosimendan treatment. These benefits were greatest for the patients with 
diminished left ventricular ejection fraction (LVEF). 
The characteristics of the cardiac surgery setting differ from the conditions in the 
context of levosimendan use in patients with acute heart failure. Factors that apply to 
cardiology patients are frequently not the same as those that apply perioperatively. 
Suspension of standard therapy in the perioperative period, use of cardiopulmonary bypass 
(CPB), blood loss, rapid intravascular and extravascular fluid shifts, and systemic 
inflammatory response syndrome can affect the impact of levosimendan treatment. This 
indicated the need for specific handling of levosimendan in cardiac surgery patients with 
respect to the definition of indications, modality of administration, and management of side 
effects.  
Therefore, 27 experts from 18 countries convened to review the literature and to agree 
upon a series of recommendations. The panellists are all recognized specialists in the fields of 
cardiothoracic anaesthesiology, cardiothoracic surgery, cardiology, cardiovascular 
pharmacology, and intensive care medicine. They extensively discussed the preoperative use 
of levosimendan, and formulated a list of questions. Thereafter, the panellists received a 
questionnaire and responded through internet voting. The results are presented here, together 
with the evidence of the pharmacology of levosimendan, and a discussion of the available 
clinical data.  
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2. Pharmacology of the cardioprotective effects of levosimendan  
 
Levosimendan is characterised by a triple mechanism of action [8]; i.e., it acts via calcium-
dependent binding to cardiac troponin C, and opens the KATP channels on smooth muscle cells 
in the vasculature, and in cardiac mitochondria. This binding of levosimendan to troponin C 
and the opening of the of KATP channels on smooth muscle cells in the vessels results in its 
inotropic and vasodilatory effects, respectively, while the opening of KATP channels in cardiac 
mitochondria is believed to be a cardioprotective pathway [15]. The definition of 
cardioprotection, however, is very broad, and it can be divided into at least two categories of 
effects: short-term and long-term cardioprotection. Short-term cardioprotection encompasses 
effects such as preconditioning, postconditioning, and anti-stunning, as well as anti-ischaemic 
effects. Long-term cardioprotection, on the other hand, is often referred to as having anti-
remodelling, anti-apoptotic and anti-inflammatory effects.  
 
2.1. Preconditioning effects of levosimendan 
The opening of KATP channels in the mitochondria has a predominant role in the protection of 
the myocardium from ischaemia and reperfusion injury [16]. By attenuation of calcium 
accumulation in the mitochondria and stabilisation of the mitochondrial inner membrane 
permeability, KATP channel opening results in a reduction in myocardial cell necrosis and 
apoptosis induced by ischaemia–reperfusion injury. Therefore, treatment with the KATP 
channel opener levosimendan prior to myocardial ischaemia will mimic ischaemic 
preconditioning. According to ex-vivo data obtained by Toit and colleagues, levosimendan 
preconditioning can reduce infarct size by 90% [11]. Also, when compared with milrinone in 
an animal model setting, there was less mortality with levosimendan: after occlusion and 
reperfusion of the coronary vessels, 70% of dogs treated with levosimendan before 
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ischaemia–reperfusion survived, as compared to 20% of those treated with milrinone [17]. In 
another model, the lactate/ pyruvate ratio in the ischaemic areas was reduced with 
levosimendan treatment prior to induction of ischaemia [18]. Finally, Kersten and co-workers 
also showed that levosimendan has protective effects against myocardial ischaemia in a dog 
model: with levosimendan treatment, infarct size was decreased by 50% [19]. 
 
2.2. Anti-stunning effects of levosimendan 
Myocardial stunning occurs when acute myocardial ischaemia leads to a transient impairment 
of the contractile function. In patients with coronary artery disease, repeated episodes of 
demand ischaemia can lead to cumulative stunning, which has been suggested to be a factor in 
the development of chronic post-ischaemic left ventricular dysfunction [20].  
Sonntag and co-workers demonstrated the anti-stunning effects of levosimendan in 24 
patients with acute coronary syndrome, whereby as compared to placebo, the total number of 
hypokinetic segments was significantly decreased with levosimendan treatment [21]. In 30 
patients with acute myocardial infarction who experienced myocardial stunning after 
emergency percutaneous coronary intervention, continuous infusion of levosimendan 0.1 
μg/kg/min for 24 h significantly improved myocardial function, as compared to placebo [22]. 
In a recent randomised, double-blind clinical trial with 61 patients who developed clinical 
signs of heart failure within 48 h of primary percutaneous-coronary-intervention–treated 
STEMI (including cardiogenic shock), 25-h treatment with levosimendan showed 
significantly greater improvement in their wall motion score index from baseline to day 5, as 
compared to placebo [23]. 
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2.3. Anti-ischaemic effects of levosimendan 
In a rodent model of healed myocardial infarction, Levijoki and co-workers showed that 
treatment with levosimendan correlated with decreased mortality [13]. These preclinical data 
were confirmed more recently in another study [24].  
 
3. Pharmacokinetic and pharmacodynamic considerations  
 
Levosimendan has a half-life for elimination of about 1 h. Without a loading dose, a steady-
state concentration can be achieved approximately 4 h after the start of continuous 
levosimendan infusion. After the infusion, the levosimendan serum concentrations decrease 
relatively rapidly. Levosimendan, however, has an active circulating metabolite known as 
OR-1896, which has a half-life for elimination of approximately 80 h [25]. In patients with 
heart failure, OR-1896 reaches its peak level approximately 2 days after the end of a 24-h 
infusion of levosimendan, and is removed from the circulation over the following 2 weeks 
[25]. Lilleberg and colleagues showed that levosimendan treatment of patients with heart 
failure for 24 h improves cardiac output and reduces pulmonary capillary wedge pressure 
(PCWP) for at least 1 week [26]. A reduction in the N-terminal-pro-atrial natriuretic peptide 
levels was observed for at least 2 weeks. 
In the cardiac surgery setting, OR-1896 can be found in the plasma, but compared to 
heart failure patients, its formation occurs at a slower pace [27]. Peak levels are observed 5 
days to 6 days after the discontinuation of levosimendan infusion. This is probably due to 
preoperative fasting and to the use of broad-spectrum antibiotics in cardiac surgery. Clinical 
data obtained in patients with low preoperative LVEF (≤30%) scheduled for elective cardiac 
surgery indicated a prolonged effect of levosimendan on the stroke volume index [28]. The 
patients received either levosimendan 0.1 µg/kg/min infusion for 19 h or milrinone 0.5 
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µg/kg/min infusion for 83 h. Within the first few hours, the effects on stroke volume index 
were comparable in both groups, but a more pronounced effect was seen with levosimendan 
during the follow-up period for up to 48 h, even though levosimendan treatment had already 
been discontinued (Figure 1). 
By overviewing the pharmacodynamic and pharmacokinetic properties of 
levosimendan, it becomes clear that its preoperative, or alternatively perioperative, use might 
have effects that are very different. Indeed, in the preoperative settings, the cardioprotective 
effects of levosimendan would have a major role along with its haemodynamic effects 
(inotropic and vasodilatory), and levosimendan might be further differentiated from other 
inodilatory, haemodynamically active or vasoactive drugs. 
 
4. Published data on the preoperative and perioperative use of levosimendan 
 
In the systematic analysis of the literature, the data sources used were PubMed, Index 
Medicus, Excerpta Medica, Reference Update, BIOSIS, and Science Citation Index. The 
pertinent studies were independently identified by two trained investigators (updated March 
27, 2014). The papers and abstracts found by searching ([levosimendan OR Simdax] AND 
[surgery OR bypass OR valve OR CABG OR anest*]) were selected according to the 
PRISMA search and the inclusion strategy described in Figure 2, and grouped according to 
the timing of the use of levosimendan and the type of intervention, as in the following 
sections.  
 
4.1. Preoperative use in on-pump cardiac surgery 
 
4.1.1. Coronary artery bypass grafting surgery 
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In a randomised, double-blind, placebo-controlled trial by Tritapepe and coworkers, 
levosimendan 24 μg/kg infusion for 10 min before initiation of coronary artery bypass 
grafting (CABG) led to significant reductions in tracheal intubation time, length of Intensive 
Care Unit (ICU) stay (P <0.01 for both), and the proportion of patients requiring inotropic 
support for >12 h (3.8% vs. 18.0% for placebo; P = 0.021) [29]. As compared to placebo, 
levosimendan-treated patients had significantly lower postoperative troponin I levels (Figure 
3) and a significantly higher cardiac index (P <0.0001 each).  
The preoperative use of levosimendan in high-risk patients with severe left ventricular 
dysfunction (LVEF <25%) scheduled for CABG was assessed in a randomised, placebo-
controlled trial [30]. Levosimendan was started 24 h before surgery, with a loading dose of 10 
μg/kg infusion for 1 h that was followed by continuous infusion of 0.1 μg/kg/min infusion for 
23 h. Overall, 252 patients participated in the study. Levosimendan reduced mortality 
compared to placebo (3.9% vs. 12.8%; P <0.05), and decreased the incidence of LCOS (7.1% 
vs. 20.8%; P <0.05) and of complicated weaning from CPB (2.4% vs. 9.6%; P <0.05). The 
levosimendan-treated group also showed lower requirement for other inotropes compared to 
placebo (7.9% vs. 58.4%; P <0.05), and for vasopressors (14.2% vs. 45.6%; P <0.05), and 
lower use of an intra-aortic balloon pump (6.3% vs. 30.4%; P <0.05).  
 
4.1.2. CABG and aortic valve surgery 
In 24 patients undergoing combined aortic valve and CABG surgery, preoperative 
levosimendan 12 μg/kg infusion for 10 min followed by a continuous infusion of 
levosimendan 0.2 μg/kg/min infusion for 24 h significantly improved cardiac index and stroke 
volume index throughout the 4-day postoperative period (P <0.05) [31]. The LVEF was 
maintained in the levosimendan group, whereas it decreased in the control group.  
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4.2. Perioperative use in on-pump cardiac surgery 
 
4.2.1. CABG surgery 
A randomised, double-blind trial assessed the effects of levosimendan on haemodynamics, 
coronary blood flow, and myocardial substrate use early after CABG [32]. Two dose 
schedules (levosimendan 8 µg/kg or 24 µg/kg as 5-min infusions after CABG) were compared 
with placebo. Although levosimendan improved cardiac performance by increasing cardiac 
output and coronary sinus blood flow, it did not increase myocardial oxygen consumption or 
change myocardial substrate use. 
De Hert and co-workers conducted a randomised study with 30 patients scheduled for 
CABG with preoperative LVEF ≤30% [28]. In addition to dobutamine, the patients received 
either milrinone 0.5 µg/kg/min infusion or levosimendan 0.1 µg/kg/min infusion immediately 
after the release of the aortic crossclamp. These infusions were continued until weaning from 
inotropic support. The stroke volume index declined 12 h after surgery in the milrinone group, 
but not in the levosimendan group (P <0.05) despite similar filling pressures. Total dose, 
duration of inotropic drug administration, and norepinephrine doses were significantly lower 
with levosimendan (P <0.05). Moreover, the duration of tracheal intubation was shorter in the 
levosimendan-treated group (P = 0.008).  
Levin and colleagues compared levosimendan (10 μg/kg as 1 h infusion followed by 
0.1 μg/kg/min infusion for 24 h) and dobutamine (starting dose, 5 μg/kg/min infusion) in a 
randomised trial with 137 patients with LCOS after surgery [33]. Patients treated with 
levosimendan experienced significant benefits in the postoperative period, with improvements 
in haemodynamic parameters with levosimendan that were greater and occurred earlier than 
with dobutamine. Postoperative mortality was lower in the levosimendan group compared to 
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dobutamine (8.7% vs. 25%; P <0.05), as was the need for vasopressors, second or third 
inotropes, and intraaortic balloon pump (IABP) use (Figure 4). 
In the randomised, double-blind LEWE study, levosimendan facilitated weaning from 
CPB and reduced the need for additional inotropic or mechanical circulatory support in 
patients with impaired LVEF (50%) undergoing CABG [34]. Sixty patients received either 
levosimendan as a 12 µg/kg bolus followed by 0.2 µg/kg/min infusion, or placebo, started 
immediately after the induction of anaesthesia. Levosimendan significantly facilitated primary 
weaning from CPB as compared with placebo (P = 0.002; Figure 5). Four patients in the 
placebo group even failed the second weaning and had to be supported by IABP, as compared 
with none in the levosimendan group (P = 0.112).  
 
4.2.2. CABG and valve surgery 
In a randomised, placebo-controlled trial, Lahtinen and colleagues demonstrated that 
levosimendan treatment diminished the incidence of heart failure after heart valve or 
combined heart valve and CABG surgery [35]. Levosimendan 24 μg/kg over 30 min of 
infusion followed by 0.2μg/kg/min infusion for 24 h, or placebo, were administered after 
induction of anaesthesia. Fifteen percent of patients in the levosimendan group and 58% in 
the placebo group experienced postoperative heart failure (P <0.001). Accordingly, the use of 
rescue inotropes and IABP was significantly less in the interventional arm (P = 0.005 and P = 
0.018, respectively). The level of the myocardial fraction of creatine kinase, which is 
indicative of myocardial damage, was lower in the levosimendan group on the first 
postoperative day, compared to placebo (P = 0.011). In contrast, the use of vasopressors was 
significantly higher in the levosimendan arm due to arterial hypotension (P <0.001). Hospital 
mortality rates and 6-month mortality rates were similar in both groups.  
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4.2.3. Aortic valve surgery 
Twenty-four patients with severe aortic stenosis and left ventricular hypertrophy undergoing 
aortic valve surgery were included in a randomised, double-blind trial by Järvelä and co-
workers [36]. In patients receiving a 24-h infusion of levosimendan 0.2 μg/kg/min starting 
after the induction of anaesthesia, LVEF was maintained, while it dropped in the placebo-
treated group. This difference was not significant, however.  
Jörgensen and others found that in addition to its inotropic effects, levosimendan can 
have a positive lusitropic effect in patients with left ventricular hypertrophy, as it shortened 
isovolumic relaxation time and improved left ventricular filling [37]. This randomised, 
blinded study compared two dose schedules (0.1 µg/kg/min and 0.2 µg/kg/min infusions for 
20 min, after initial loading dose of 12 µg/kg infusion for 10 min) with placebo in 23 patients 
after aortic valve replacement for aortic stenosis. Levosimendan treatment showed a dose-
dependent increase in cardiac output (+28%; P <0.001) and stroke volume (+26%; P <0.001), 
and a decrease in systemic vascular resistance (-22%; P <0.001). There was a trend towards 
an increase in LVEF (12%; P = 0.058). After the administration of levosimendan, as 
compared to placebo, isovolumic relaxation time decreased (-3%; P <0.001), as did the 
deceleration slope of early diastolic filling (-45%; P <0.01). Both peak early diastolic filling 
velocity (16%, P <0.01) and peak late diastolic filling velocity (15%; P <0.001) increased 
significantly.  
 
4.2.4. CABG and mitral valve surgery 
A case-matched study compared levosimendan with the use of an IABP in heart failure 
patients undergoing elective CABG without or with concomitant mitral valve surgery [38]. 
Eleven patients received levosimendan infusion at a dose of 0.1 μg/kg/min for 24 h, while 
another 11 patients received preoperative IABP. The length of stay at the ICU was 
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significantly reduced in the levosimendan-treated group, compared to IAPB use (2.5 vs. 5 
days; P = 0.01).  
 
4.2.5. Mitral valve surgery 
Gandham and co-workers compared the use of levosimendan 0.1 μg/kg/min infusion with 
dobutamine 5 μg/kg/min infusion for weaning from CPB in 60 patients who were undergoing 
mitral valve repair or replacement for severe mitral stenosis [39]. The patients who received 
levosimendan showed greater reductions in systemic vascular resistance index, central venous 
pressure, and mean arterial pressure, compared to dobutamine. The requirement of inotropes 
and vasoconstrictors was increased in the levosimendan-treated group. Compared to 
dobutamine, there was a statistically significant increase in cardiac index with levosimendan, 
even 12 h after discontinuation.  
 
4.3. Off-pump cardiac surgery 
Several studies have tested the hypothesis that levosimendan treatment is associated with 
beneficial haemodynamic effects during and after off-pump CABG in patients with good 
preoperative left ventricular function. A randomised, four-times–masked, controlled study 
investigated levosimendan at two dose schedules: low dose (12 µg/kg) and high dose (24 
µg/kg) as 10 min infusions [40]. These treatments were administrated 20 min before the start 
of the surgery. Compared to placebo, significant increases in cardiac output and LVEF 
occurred after both the high-dose (P <0.001 and P = 0.006, respectively) and the low-dose (P 
= 0.001 and P = 0.002, respectively) treatments. Both levosimendan doses produced 
significant increases in stroke volume and decreases in systemic vascular resistance. 
In a double-blind randomised trial, 24 patients received either placebo or 
levosimendan at a dose of 12 µg/kg as an infusion for 15 min before CABG [41]. At 10 min 
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and 60 min post-infusion, the cardiac index and the LVEF were significantly higher with 
levosimendan than with placebo (P = 0.018 each). The stroke volume index was significantly 
higher for levosimendan at 10 min (P = 0.018), but not at 60 min (P = 0.063).  
Kodalli and colleagues compared levosimendan 0.1 μg/kg/min infusion and placebo 
after induction of general anaesthesia in a double-blind manner [42]. In patients receiving 
levosimendan, compared to placebo, the cardiac index was significantly higher and the 
systemic vascular resistance index was significantly lower at 6, 12, 18 and 24 h after CABG. 
No improvements were noted in terms of duration of ventilation or ICU length of stay.  
The double-blind, randomised trial by Shah and colleagues tested preoperatively 
administered levosimendan 200 µg/kg infusion for 24 h against placebo for off-pump CABG 
in 50 patients with left ventricular dysfunction (LVEF <30%) [43]. As compared to the 
control group, the levosimendan-treated patients had higher cardiac index and PCWP during 
the operative and early postoperative period. Also, requirements for inotropes, IABP and CPB 
support were lower for levosimendan, and both ICU and hospital length of stay were reduced.  
 
4.4. Effects of levosimendan on kidney function 
As renal dysfunction is an important complication of cardiac surgery, several trials have 
investigated the potential renal benefits mediated by levosimendan. In a randomised, placebo-
controlled study, levosimendan significantly improved renal parameters after cardiac surgery 
with CPB [44]. Levosimendan was applied as a 0.1 μg/kg/min infusion for 1 h after a loading 
dose of a 12 μg/kg infusion. When compared to placebo, this treatment caused a significant 
12% increase in renal blood flow, and a significant 21% increase in glomerular filtration rate, 
whereas renal vascular resistance decreased significantly by 18%. There were no significant 
changes in filtration fraction, renal oxygen consumption, or renal oxygen extraction. These 
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effects clearly differed from those of dopamine, which also increased renal blood flow, but 
did not increase the glomerular filtration rate.  
Baysal and co-workers compared levosimendan (6 μg/kg infusion after removal of the 
aortic cross-clamp, followed by 24-h infusion of 0.1 μg/kg/min) with placebo in addition to 
standard inotropic therapy [45]. The cohort consisted of 128 patients with LVEF ≤45% who 
were undergoing mitral valve surgery. Compared with the group of patients who received 
only standard inotropic therapy, the addition of levosimendan improved postoperative renal 
clearance on days 1 and 3. At these time points, serum creatinine levels were lower and the 
estimated glomerular filtration rates were higher than in the control arm. There was a trend in 
favour of levosimendan regarding the need for renal replacement therapy.  
A meta-analysis by Harrison and colleagues also highlighted the beneficial effects of 
perioperative levosimendan on renal function, as it showed significant reductions in the need 
for dialysis in levosimendan-treated patients (P = 0.003) [14]. A consensus paper on the 
overall renal effects of levosimendan appeared also recently in the literature [46]. 
 
4.5. Effects of levosimendan on hepatic function 
Liver dysfunction due to low cardiac output after cardiac surgery is associated with poor 
prognosis. A randomised controlled study by Alvarez and colleagues compared the effects of 
dobutamine and levosimendan on hepatic blood flow in patients with low cardiac output after 
cardiac surgery [47]. A total of 25 patients were randomised to receive either levosimendan 
12 μg/kg infusion for 15 min followed by 0.2 μg/kg/min infusion for 24 h, or dobutamine 7.5 
μg/kg/min infusion for 24 h. As compared to dobutamine, levosimendan improved systemic 
and hepatic haemodynamics (cardiac index, portal vein flow, pulsatility index) at 24 h and 48 
h. They also noted that levosimendan can be considered as a liver vasodilator that improves 
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hepatic blood flow through both the hepatic artery and the portal venous system. In contrast, 
dobutamine treatment only affected portal venous blood flow.  
 
4.6. Effects of levosimendan on right heart function 
The efficacy of levosimendan in increasing right ventricular contractility and reducing right 
ventricular afterload has been demonstrated in heart failure, cardiogenic shock related to acute 
myocardial infarction, and septic shock (for review, see Nieminen et al. 2013 [48]). 
Levosimendan also proved to be beneficial in patients with preoperative right ventricular 
dysfunction who were undergoing implantation of a left ventricular assist device [49]. 
Similarly, in a small retrospective study, Theiss and co-workers showed superior twelve-
month survival compared to INTERMACS registry data in patients with right ventricular 
dysfunction treated with levosimendan before left ventricular assist device implantation [50]. 
Finally, in a pilot study in patients with low-cardiac-output heart failure after cardiac surgery, 
Labriola and co-workers administered levosimendan and observed improved cardiac index 
and PCWP. At the same time, the mean pulmonary artery pressure and right arterial pressure 
decreased by 13% (P <0.001) and 25% (P <0.001), respectively [51]. 
 
5. Pharmaco-economic considerations 
 
Health- and pharmaco-economic analyses on the use of levosimendan in acute decompensated 
heart failure have shown that its use is cost-effective [52-54]. We did not find in the literature, 
however, systematic health economic studies on the use of levosimendan in cardiac surgery. 
From an analysis of the available data, it appeared to us that levosimendan positively affects 
the major elements which are likely to increase the costs of treatment in cardiac surgery: (1) 
the ICU stay has been reported to be shorter in several levosimendan studies [29,30]; (2) there 
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is less need for IABP (both the actual number of the patients and the duration)[28, 30, 33, 35, 
55]; and (3) there is less need for renal replacement therapy in levosimendan treated patients 
[14, 30, 33, 45]. As it regard the concomitant use of other vasoactive drug, a higher need for 
vasopressors when using levosimendan is compensated by a lower need of inotropes. Overall, 
the expectation is that levosimendan treatment in cardiac surgery would be cost-effective [56], 
despite its higher cost compared to dobutamine.  
 
6. Ongoing trials 
 
A number of European trials are currently assessing the perioperative use of levosimendan 
(see Table 3). The LICORN study is investigating the efficacy of preoperative levosimendan 
in patients with LVEF ≤40% undergoing CABG with or without valve replacement under 
CPB (study number P110138, France). The primary endpoint of this placebo-controlled study 
is a composite that includes the use of inotropic agents beyond 24 h after the end of study 
drug infusion, or the need of postoperative mechanical assist devices (IABP or others), or the 
impossibility to wean the patients from circulatory support if they were already in use 
preoperatively, or the need for renal replacement therapy. Secondary endpoints include 
mortality at days 28 and 180, each item of the primary endpoint separately, and length of ICU 
and hospital stays. Levosimendan is being administered as a 0.1 µg/kg/min infusion for 24 h 
and is started at the time of anaesthesia induction, without bolus application. The study 
population will include 340 patients.  
A recently completed (but not yet published) double-blind study by Argyriadou and 
co-workers was aimed at confirmation of the benefits of preoperative levosimendan in 
patients with left ventricular dysfunction (LVEF ≤40%) routinely scheduled for CABG 
(NCT01318460). Thirty-two patients were randomised to either levosimendan 0.1 µg/kg/min 
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infusion for 24 h before surgery, or placebo. A preliminary analysis of the data favoured 
levosimendan treatment to a significant degree: while the placebo group showed no 
significant difference between preoperative and postoperative LVEF, LVEF increased 
significantly in the levosimendan group on the 7
th
 postoperative day. Moreover, cardiac index, 
tissue perfusion, and PCWP were significantly improved in the experimental arm.  
In North America, a randomised, placebo-controlled, phase III pivotal trial in high-risk 
patients undergoing CABG (LVEF ≤25%) and/or mitral or aortic valve surgery (LVEF ≤35%) 
started in the third quarter of 2014 (NCT02025621). A total of 760 patients in 50 cardiac 
surgery centres across North America will receive either levosimendan 0.2 µg/kg/min 
infusion for 1 h followed by 0.1 µg/kg/min infusion for 23 h, or placebo. Infusion will be 
started before surgery. Co-primary endpoints comprise death, use of mechanical assist devices 
(IABP, left ventricular assist device), myocardial infarction, and dialysis. Secondary 
endpoints include postoperative duration of stay at the ICU or coronary care unit, and 
incidence of LCOS. The safety endpoint is the all-cause mortality by day 90.  
Finally, the study of levosimendan in high-risk patients undergoing cardiac surgery 
(HSR-LEVO) is comparing levosimendan to placebo on mortality and morbidity in 1000 
patients at risk of LCOS, and this is currently recruiting (NCT00994825). An interim analysis 
of the data is planned after the first 250 patients. 
 
7. Composition of the panel and mode of agreement on the recommendations 
 
The panellists were 27 experts from 18 countries (Austria, Belgium, Croatia, Czech Republic, 
Finland, France, Germany, Greece, Hungary, Israel, Italy, Russia, Slovenia, Spain, Sweden, 
Switzerland, the U.K., and the U.S.A.), all of whom were recognized specialists in the fields 
of cardiothoracic anaesthesiology, cardiothoracic surgery, cardiology, cardiovascular 
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pharmacology, and intensive care medicine. They were invited to join the panel by the 
chairmen (WT, MH, FG), on the basis of their experience with preoperative and perioperative 
use of levosimendan documented in the literature. 
After discussing the available evidence on preoperative and intraoperative use of 
levosimendan, the panel found that the rationale for preoperative use of levosimendan is 
profoundly different from that for its perioperative (or intraoperative) use. Indeed, 
intraoperatively, levosimendan is primarily used for its inodilatory effects, which can be 
achieved without any negative impact on myocardial oxygen balance. In contrast, in the 
preoperative setting, levosimendan is used also in an attempt to provide patient benefit 
through its cardioprotective properties that come into effect later during the intraoperative 
period.  
For the sake of clarity, the panel decided to discuss these two applications of 
levosimendan separately. The panel recognized that the use of levosimendan in the 
perioperative setting had already been reviewed and discussed by Toller et al. [66]. The 
recommendations of Toller et al. [66] on the operative use of levosimendan were embraced by 
the present panel of experts. 
The panel thus decided to limit the present consensus to the preoperative use of 
levosimendan. The panel agreed on a series of questions and took a vote on the following 
questions: (1) which patients could benefit from the preoperative use of levosimendan and in 
which kind of procedures, (2) at which doses and timing should levosimendan be 
administered, and finally (3) which potential side effects of a preoperative use of 
levosimendan have to be taken into account and how to best prevent and treat them. These 
were answered electronically and anonymously by 24 respondents (all of the authors, with the 
exception of PP and MK, to avoid any conflict of interest, and of RHM, because the use of 
levosimendan in U.S.A. has not yet been approved), on the basis of (i) their experience with 
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levosimendan, and (ii) the knowledge in the available literature. The answers were disclosed 
to the group and a second round of opinion was allowed to agree on some recommendations 
(see votes by the experts in Table 2). 
 
8. Conclusions of the panel 
 
Clinical studies show that levosimendan effectively improves general and pulmonary 
haemodynamics in patients undergoing cardiac surgery, thereby reducing the need for 
inotropic agents and mechanical circulatory support, and additionally optimising renal and 
hepatic function. In general, the length of stay on the ICU and in the hospital is shortened. 
Overall, levosimendan treatment is considered as a kind of “safety net” in the surgical setting. 
The unique inotropic and cardioprotective properties of levosimendan can provide sustained 
effects for several days and can thus help to reduce complications in the postoperative period. 
On the other hand, vasodilation occurs with this treatment, which can necessitate the 
administration of vasopressors.  
The panellists recommended preoperative use of levosimendan in patients with 
generally compromised myocardial function, including right ventricular dysfunction. They 
advised against a bolus injection when used outside the operation room. The day prior to 
surgery was suggested as the optimal time point for initiation of a preoperative therapy with 
levosimendan. The recommended dose of levosimendan agreed upon was 0.1 µg/kg/min 
infusion for 24 h, or to the end of the vial. When levosimendan infusion is started during or 
after induction of anaesthesia, the addition of a bolus is considered to be a feasible option.  
Levosimendan can be administered in any hospital setting, provided that 
haemodynamic monitoring is guaranteed. In fact, as levosimendan produces significant dose-
dependent increases in stroke volume and cardiac output, and decreases in pulmonary 
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capillary wedge pressure, mean blood pressure, mean pulmonary artery pressure, mean right 
atrial pressure, and total peripheral resistance [48], it should be administered in a safe and 
adequately monitored environment, ready to prevent and treat side effects. If vasodilation 
occurs, the experts suggest the combination of levosimendan with norepinephrine or 
vasopressin. If additional inotropic support becomes necessary in a levosimendan-treated 
patient, dobutamine should be the preferred inotrope.  
In general, the data so far collected are promising, but it was noted that only some of 
the clinical studies are robust, as many trials were conducted in relatively few patients, thus 
the scientific evidence for use of levosimendan is yet to be further expanded. Since all of the 
meta-analyses on operative use of levosimendan to date [14, 67-70] show positive benefits 
from levosimendan, there is a strong rationale for further expansion of the data pool. Clinical 
trials currently ongoing in Europe and the USA are expected to contribute significantly, and 
to possibly support further the existing data. In the phase of revision of this manuscript a 
Bayesian network meta-analysis on the effect of inodilatory agents on mortality was 
published [71] in which it was shown that levosimendan has 90% probability to be the best in 
improving survival in cardiac surgery when compared with PDE inhibitors, dobutamine, and 
placebo.    
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Table 1: Studies on preoperative and perioperative use of levosimendan (from PubMed). 
 
First author Title Type of study/ 
comparator 
Number of 
patients 
Levosimendan dosing/ timing of 
dose 
Results 
ON-PUMP PREOPERATIVE     
CABG      
Tritapepe 2009 [29] Levosimendan pre-treatment improves 
outcomes in patients undergoing 
CABG 
Randomised, 
double-blind / vs. 
placebo 
106 (2× 53) 24 μg/kg for 10 min infusion 
before the initiation of bypass 
Significant reductions in tracheal intubation time, length of ICU 
stay and number of patients requiring inotropic support for >12 h 
with levosimendan. Significantly lower postoperative troponin I 
concentrations and higher cardiac index 
Levin 2012 [30] Preoperative levosimendan decreases 
mortality and the development of low 
cardiac output in high-risk patients with 
severe left ventricular dysfunction 
undergoing CABG with 
cardiopulmonary bypass (EF<25%) 
Randomised / vs. 
placebo 
253 (127 vs. 
125) 
Loading dose (10 μg/kg), 23 h 
infusion (0.1 μg/kg/ min) 
Levosimendan group had a lower incidence of complicated 
weaning from CPB (2.4% vs. 9.6%;P <0.05), decreased mortality 
(3.9% vs. 12.8%; P <0.05) and a lower incidence of LCOS (7.1% 
vs. 20.8%; P <0.05) compared with the control group, lower 
requirement for inotropes (7.9% vs. 58.4%; P <0.05), 
vasopressors (14.2% vs. 45.6%; P <0.05) and intra-aortic balloon 
pumps (6.3% vs. 30.4%; P <0.05) 
Dogan 2013 [57] Levosimendan use decreases atrial 
fibrillation in patients after CABG: a 
pilot study 
Prospective, 
randomised / vs. 
placebo 
200 (2× 100) Levosimendan started 6 h before 
operation. In the operating room, 
levosimendan continued at 24 
μg/kg as a slow drip through the 
central venous catheter and stopped 
before the initiation of CPB. 
During the rewarming period, 
levosimendan was started again via 
the central vein with the same 
dose. 
Postoperative AF in levosimendan group was reduced in patients 
with poor left ventricle function after CABG operations. C-
reactive protein was higher postoperatively in the control 
Eris 2014 [56] Preoperative uses of levosimendan in 
patients undergoing CABG 
(LVEF<30%) 
Retrospective / 
levosimendan 
infusion applied 12 
h before operation 
(G1), after 
induction of 
anaesthesia (G2), 
during the pump 
removal (G3) and 
non-LS control 
(G4). 
40 (4× 10) (0.2 μg/kg/min infusion) Increase of LVEF; infusion of levosimendan 12 h before surgery 
produced less myocardial damage 
CABG+AORTIC VALVE     
Leppikangas 2011 
[31] 
Preoperative levosimendan infusion in 
combined aortic valve and coronary 
bypass surgery 
Randomised / vs. 
placebo 
24 (2× 12) 12 μg bolus for 10 min followed by 
0.2 μg/kg/min infusion for 24 h; 
treatment was started on the day 
before surgery 
Higher cardiac index and stroke volume index with levosimendan 
for the 4-day postoperative period (P <0.05). LVEF maintained 
(the control group showed a decrease) 
ON-PUMP PERIOPERATIVE     
CABG      
Lilleberg 1998 [32] Effects of levosimendan on Randomised, 23 (8, 8, 7) Two dose schedules: 8 µg/kg or 24 Heart rate increased significantly after the higher dose; cardiac 
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haemodynamics, coronary blood flow, 
and myocardial substrate use early after 
CABG 
double-blind / vs. 
placebo 
µg/kg infusions after CABP output increased significantly after both doses, while systemic 
and pulmonary vascular resistance decreased significantly. 
Coronary sinus blood flow increased after both doses 
Nijhawan 1999 [58] Levosimendan enhances cardiac 
performance after cardiopulmonary 
bypass: a prospective, randomised 
placebo-controlled trial 
Prospective, 
randomised, 
double-blind / vs. 
placebo 
18 (3× 6) Two dose schedules: 18 (low dose) 
or 36 (high dose) µg/kg bolus and 
0.2 (low dose) or 0.3 (high dose) 
µg/kg/min infusion. Administration 
started before separation from CPB 
and was continued for 6 h after 
CPB 
Placebo patients experienced significant increases in heart rate 
and decreases in systemic vascular resistance 15 min after CPB, 
as well as later increases in mean arterial pressure and cardiac 
output and decreases in stroke volume and pulmonary vascular 
resistance. Heart rate was greater in patients receiving high-dose 
but not low-dose levosimendan versus placebo immediately after 
CPB. Mean arterial pressure also was lower in patients treated 
with either levosimendan dose compared with placebo after CPB. 
Levosimendan increased cardiac output and decreased systemic 
vascular resistance.  
Alvarez 2005 [59] Hemodynamic effects of levosimendan 
following cardiac surgery 
Randomised / vs. 
dobutamine 
30 (2× 15) Loading dose 18 µg/kg in 15-20 
min infusion followed by 24-h 
infusion of 0.2 µg/kg/ min 
Heart rate and cardiac index increased in the levosimendan group 
only (P <0.05). MAP, systemic and pulmonary vascular 
resistance decreased significantly in the levosimendan group (P 
<0.05) only.  
Alvarez 2006 [60] Hemodynamic effects of levosimendan 
compared with dobutamine in patients 
with low cardiac output after cardiac 
surgery 
Randomised / vs. 
dobutamine 
41 (20 vs. 21) Loading dose 12 µg/kg infusion 
followed by 24-h infusion of 0.2 
µg/kg/min 
Levosimendan improved cardiac index more than dobutamine 
(2.4 [0.2] vs. 2.9 [0.3] l/min/m2, respectively, at 24 h; P <0.05) 
and reduces systemic and pulmonary vascular resistance, 
decreases systemic arterial, pulmonary arterial, pulmonary 
capillary wedge, and central venous pressure 
Al-Shawaf 2006 
[61] 
Levosimendan or milrinone in the type 
2 diabetic patient with low LVEF 
undergoing elective coronary artery 
surgery 
Randomised / vs 
milrinone 50 µg/kg 
for 10 min 
followed by 0.3 to 
0.5 µg/kg/min 
infusion for 24 h 
30 (14 vs. 16) 12 µg/kg bolus for 10 min 
followed by 0.1 to 0.2 µg/kg/min 
infusion for 24 h 
Significantly higher cardiac index and mixed venous oxygen 
saturation with levosimendan; significantly lower pulmonary 
capillary wedge pressure, systemic vascular resistance and 
oxygen extraction ratios 
Akgul 2006 [55] Levosimendan for weaning from 
cardiopulmonary bypass after CABG 
Prospective 15 12-24 µg/kg loading dose for 10 
min infusion followed by 0.1-0.2 
µg/kg/min infusion for 24 h 
All patients showed evidence of hemodynamic improvement with 
the start of LS infusion, and 93.3% were successfully weaned 
from CPB. 53.3% experienced significant increases in cardiac 
index and blood pressure, leading to a lessening of the need for 
catecholamine support 
De Hert 2007 [28] The effects of levosimendan in cardiac 
surgery patients with poor left 
ventricular function 
Randomised / vs. 
milrinone 
0.5mg/kg/min 
infusion 
30 (2× 15) 0.1 mg/kg/min infusion started 
immediately after the release of the 
aortic crossclamp, continued until 
weaning from inotropic support 
Stroke volume declined 12 h after surgery in the milrinone group 
but not in the LS group (P <0.05) despite similar filling pressures. 
Total dose, duration of inotropic drug administration and 
norepinephrine dose were lower with levosimendan (P <0.05). 
The duration of tracheal intubation was shorter with 
levosimendan (P = 0008). Three patients in the milrinone group 
but none in the levosimendan group died within 30 days of 
surgery 
Levin 2008 [33] Levosimendan gives superior results to 
dobutamine in postoperative low 
cardiac output syndrome 
Randomised /vs. 
dobutamine 5 
µg/kg/min infusion 
137 (69 vs. 
68) 
10 µg/kg loading dose followed by 
0.1 µg/kg/min infusion for 24 h 
Improvement of hemodynamic parameters was greater with 
levosimendan and occurred earlier. Postoperative mortality was 
lower (8.7% vs. 25%; P <0.05), as were major postoperative 
complications. The need for additional inotropic drug treatment, 
vasopressor therapy or balloon counterpulsation was lower. 
Levosimendan-treated patients experienced shorter ICU stay 
Eriksson 2009 [27] Levosimendan facilitates weaning from 
cardiopulmonary bypass in patients 
Prospective, 
randomised, 
60 (2× 30) 12 µg/kg bolus for 10 min 
followed by 0.2 µg/kg/min infusion 
Levosimendan significantly enhanced primary weaning from 
CPB compared with placebo (P = 0.002). Four patients in the 
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undergoing CABG with impaired left 
ventricular function 
double-blind / vs. 
placebo 
for 24 h; administration was started 
immediately after induction of 
anaesthesia 
placebo group failed the second weaning and underwent IABP 
compared with none in the levosimendan group (P = 0.112). 
Lomivorotov 2011 
[62] 
Levosimendan versus intra-aortic 
balloon pump in high-risk cardiac 
surgery 
Randomised / vs. 
preoperative IABP 
40 (2× 20) 12 μg bolus for 10 min followed by 
0.2 μg/kg/min infusion for 24 h; 
treatment was started after 
induction of anaesthesia 
Significantly lower levels of troponin I at 6 h after surgery with 
levosimendan, significantly shorter intensive care unit stay 
Lomivorotov 2012 
[63] 
Levosimendan versus an intra-aortic 
balloon pump in high-risk cardiac 
patients. 
 90 (3× 30)  Levosimendan caused significantly increased cardiac index 5 min 
after CPB, at the end of the operation, and 2 h and 4 h after 
perfusion. Significantly lower level of troponin I 6 h after 
surgery, significantly shorter stay at the intensive care unit  
CABG+VALVE      
Tasouli 2007 [64] Efficacy and safety of perioperative 
infusion of levosimendan in patients 
with compromised cardiac function 
undergoing open-heart surgery: 
importance of early use 
Randomised: 
during or after 
open-heart surgery 
45 0.1 µg/kg min without loading 
dose for 24-48 h 
ICU stay and hospital stay were significantly decreased when 
levosimendan was started in the operating theatre already rather 
than at the ICU 
Lahtinen 2011 [35] Levosimendan reduces heart failure 
after cardiac surgery: a prospective, 
randomised, placebo-controlled trial 
Prospective, 
randomised /vs. 
placebo 
200 (99 vs. 
101) 
24 μg/kg bolus over 30 min 
followed by 0.2 μg/kg/min infusion 
for 24 h 
Levosimendan led to a reduced incidence of heart failure, but was 
associated with arterial hypotension and increased requirement of 
vasopressor agents postoperatively 
Järvelä 2008 [36] Levosimendan in aortic valve surgery: 
cardiac performance and recovery 
Prospective, 
randomised, 
double-blind /vs. 
placebo 
24 (2× 12) 0.2 μg/kg/min infusion for 24 h 
beginning after the induction of 
anaesthesia 
LVEF was maintained with levosimendan but dropped with 
placebo (n.s.) 
Jörgensen 2008 [37] Effects of levosimendan on left 
ventricular relaxation and early filling 
at maintained preload and afterload 
conditions after aortic valve 
replacement for aortic stenosis 
Prospective, 
randomised, 
blinded /vs. 
placebo 
23 (12 vs. 11) Two dose schedules: 0.1 or 0.2 
µg/kg/min infusion for 20 min after 
initial loading doses of 12 µg/kg 
infusion for 10 min 
Levosimendan gave rise to dose-dependent increases in cardiac 
output (28%; P <0.001) and stroke volume (26%; P <0.001) as 
well as decreases in systemic vascular resistance (-22%; P 
<0.001). Trend for an increase in LVEF. Decreases in isovolumic 
relaxation time and deceleration slope of early diastolic filling; 
increased peak early diastolic filling velocity and peak late 
diastolic filling velocity 
CABG + MITRAL      
Severi 2011 [38] Levosimendan versus intra-aortic 
balloon pump in high-risk cardiac 
surgery patients 
Case-matched / vs. 
preoperative IABP 
22 (2× 11) 0.1 μg/kg/min infusion for 24 h Shorter duration of ICU stay with levosimendan (2.5 vs. 5 days; P 
= 0.01) 
MITRAL      
Gandham 2013 [39] A comparison of hemodynamic effects 
of levosimendan and dobutamine in 
patients undergoing mitral valve repair 
/ replacement for severe mitral stenosis 
Randomised / vs. 
dobutamine 5 
μg/kg/min infusion 
60 (2× 30) 0.1 μg/kg/min infusion while 
weaning off CPB 
Increased vasodilation and lesser inotropic activity with 
levosimendan, statistically significant increase in cardiac index 
even after 12 h of discontinuation. Increased requirement of 
inotropes and vasoconstrictors 
OFF-PUMP      
Barisin 2004 [40] Levosimendan in off-pump coronary 
artery bypass: a four-times masked 
controlled study 
Randomised, four-
times masked /vs. 
placebo 
31 (11, 10, 
10) 
Two dose schedules: low dose (12 
µg/kg), high dose (24 µg/kg) over 
10 min; treatment was given 20 
min before start of surgery  
Significant increases in cardiac output and LVEF occurred after 
high-dose (P <0.001; P = 0.006) and low-dose levosimendan (P = 
0.001; P = 0.002). Both levosimendan doses produced significant 
increased stroke volume and decreased systemic vascular 
resistance. 
Husedzinović 2005 
[41] 
Levosimendan as a new strategy during 
off-pump CABG: double-blind 
randomised placebo-controlled trial 
Randomised, 
double-blind /vs. 
placebo 
24 (2× 12) 12 µg/kg bolus for 15 min before 
surgery 
Cardiac index and LVEF were significantly higher 10 min and 60 
min (P = 0.018 for all) after levosimendan administration. After 
60 min, cardiac index increased from 2.18 to 2.84 l/min/m2. 
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Stroke volume index was significantly higher at 10 min (P = 
0.018), but not at 60 min (P = 0.063) 
Kodalli 2013 [42] Effect of levosimendan on 
hemodynamic changes in patients 
undergoing off-pump CABG: a 
randomised controlled study 
Randomised /vs. 
placebo 
30 (2× 15) 0.1 μg/kg/min infusion during 
surgery  
Significant increase of cardiac index and significant decrease of 
vascular resistance index with levosimendan at 6, 12, 18 and 24 h 
after surgery. No outcome benefit in terms of duration of 
ventilation or ICU stay 
Shah 2014 [43] Levosimendan during off-pump CABG 
in patients with LV dysfunction 
Randomised 
double-blind /vs. 
placebo 
50 (2× 25) 200 µg/kg infusion in 24 h Levosimendan increased cardiac index during operative and early 
operative period. Levosimendan-treated patients had less 
requirement for inotropes, IABP, CPN, ICU stay and hospital 
stay. 
MAINLY DESCRIBING RENAL FUNCTION     
Ristikankare 2012 
[65] 
Effects of levosimendan on renal 
function in patients undergoing 
coronary artery surgery 
Prospective, 
randomised, 
double-blind 
substudy /vs. 
placebo 
60 (2× 30) 12 μg/kg bolus for 10 minutes 
followed by 0.2 μg/kg/min infusion 
for the next 23 h and 50 min 
No significant changes in plasma creatinine, serum cystatin C, 
and urine NAG at any of the measuring points 
Bragadottir 2013 
[44] 
Effects of levosimendan on glomerular 
filtration rate, renal blood flow, and 
renal oxygenation after cardiac surgery 
with cardiopulmonary bypass: a 
randomised placebo-controlled study 
Prospective, 
randomised /vs. 
placebo 
30 (2× 15) 0.1 μg/kg/min infusion for 1 h after 
a loading dose of 12 μg/kg 
Increases in cardiac index (22%), stroke volume index (15%) and 
heart rate (7%) with levosimendan over placebo, decreased 
systemic vascular resistance index (21%). Significant increases in 
renal blood flow (12%, P <0.05) and glomerular filtration rate 
(21%, P <0.05), decreased renal vascular resistance (18%, P 
<0.05).  
Baysal 2014 [45] Levosimendan improves renal outcome 
in cardiac surgery: a randomised trial 
Randomised /vs. 
placebo on top of 
standard inotropic 
therapy. 
280 (2× 64) Loading dose (6 μg/kg) after 
removal aortic cross-clamp, 24 h 
infusion (0.1 μg/kg/min) in 
addition to standard inotropic 
therapy. 
Valve surgery improved immediate postoperative renal function 
(eGFR) and reduced need for renal replacement therapy 
MAINLY DESCRIBING LIVER FUNCTION     
Alvarez 2013 [47] A comparison of dobutamine and 
levosimendan on hepatic blood flow in 
patients with a low cardiac output state 
after cardiac surgery: a randomised 
controlled study 
Randomised /vs. 
dobutamine 7.5 
μg/kg/min infusion 
for 24 h  
25 Levosimendan (12 μg/kg infusion) 
over 15 min + infusion of 0.2 
μg/kg/min for 24 h 
The systemic and hepatic haemodynamics at 24 h and 48 h were 
all better after levosimendan than dobutamine. Levosimendan is 
selective liver vasodilator and improves hepatic blood flow 
through both the hepatic artery and portal venous system.  
MAINLY DESCRIBING RIGHT HEART FUNCTION     
Sponga 2012 [49] Preoperative treatment with 
levosimendan in candidates for 
mechanical circulatory support.   
Consecutive 21 Levosimendan 0.1 to 0.2 
mg/kg/min infusion for a 
maximum of 48 h without bolus. 
Levosimendan improves preoperative hemodynamic conditions in 
LVAD candidates with borderline right ventricular function. 
Labriola 2004 [51] Haemodynamic effects of 
levosimendan in patients with low-
output heart failure after cardiac 
surgery.   
Consecutive 11 Levosimendan 12 g/kg over 10 
minutes, followed by a continuous 
infusion of 0.1 g/kg/min for 12 h 
Levosimendan  improves cardiac index, and reduces PCWP, 
mean pulmonary artery pressure and right arterial pressure 
Theiss 2004 [50] Preconditioning with levosimendan 
before implantation of left ventricular 
assist devices. 
Retrospective, 
consecutive 
9 Levosimendan continuous infusion 
of 0.1 g/kg/min for 24 h 
Levosimendan  improved clinical outcome and survival when 
used as pretreatment in patients with right heart insufficiency 
prior to LVAD implantation 
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Table 2: Opinions of the 24 European experts on the preoperative use of levosimendan in cardiac surgery. 
1. Type of patient 
Which type of cardiac surgical patients would you suggest to give preoperative 
levosimendan? 
Definitely yes 
Neutral opinion/ 
no direct experience/no answer 
Definitely no 
CABG with low LVEF 100% 0% 0% 
CABG plus mitral valve surgery 71% 29% 0% 
Mitral valve replacement plus aortic valve replacement 29% 71% 0% 
Mitral valve replacement 33% 67% 0% 
Aortic stenosis with low LVEF 50% 33% 17% 
Aortic regurgitation with low LVEF  54% 38% 8% 
  
Type of cardiac surgical patients who was shown in literature to benefit from 
preoperative levosimendan.  
Convincing evidence Some evidence Scarce/no evidence 
CABG with low LVEF 92% 8% 0% 
CABG plus mitral valve surgery 50% 29% 21% 
Mitral valve replacement plus aortic valve replacement 17% 50% 33% 
Mitral valve replacement 17% 58% 25% 
Aortic stenosis with low LVEF 21% 54% 25% 
Aortic regurgitation with low LVEF 17% 46% 38% 
Would you suggest giving preoperative levosimendan in generally compromised 
myocardial function, including right ventricular dysfunction? 
100% YES 
Would you suggest giving preoperative levosimendan in high-risk surgery (recent 
myocardial infarction, age, forecasted long ischaemic period) independently of LVEF, 
EuroSCORE or cardiac score?  
67% YES 
Would you suggest preoperative administration of dobutamine in high-risk cases (see 
above questions)? 
92% NO 
Would you suggest giving levosimendan before left ventricular assist device 
implantation to support the right ventricle? 
96% YES 
Would you suggest to give preoperative levosimendan in pulmonary hypertension and 
right ventricle failure (e.g. during cardiac transplantation)? 
92% YES 
Would you suggest preoperative levosimendan in patients undergoing Mitraclip 
procedure for functional/ischaemic mitral regurgitation? 
75% YES 
Would you suggest preoperative levosimendan in patients undergoing transcatheter 
aortic valve implantation when LVEF is <35%? 
63% NO 
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2. Modality of administration 
Where would you suggest preoperative levosimendan to be given? (multiple answers 
are allowed) 
On surgical ward In ICU Any place BUT under 
hemodynamic 
monitoring and clinical 
control 
3/24 5/24 21/24 
Which dose regimen would you recommend for preoperative levosimendan to be given 
on the day prior to surgery? (multiple answers are allowed) 
Bolus +infusion Bolus alone Infusion without bolus 
0/24 0/24 24/24 
Which dose regimen would you recommend for preoperative levosimendan to be given 
on induction of anaesthesia? (multiple answers are allowed) 
Bolus +infusion Bolus alone Infusion without bolus 
7/24 0/24 19/24 
In case of bolus administration, which dose would you suggest? 6 µg/kg 12 µg/kg 24 µg/kg 
67% 29% 4% 
What dose of levosimendan would you suggest for continuous infusion? 0.1 µg/kg/min 0.2 µg/kg/min 0.3 µg/kg/min
 
or higher 
83% 17% 0% 
How long shall the infusion last after surgery?  24h eventually less than 24h 
 (to the end of the vial) 
more than 24h 
44% 50% 4% 
Would you suggest a second dose in a patient 
in whom a first dose had no effect? 
63% NO 
When would you suggest a second dose to be given in a patient in whom a first dose 
worked well? 
After 3-4 days 
92% 
Just following the first dose 
8% 
If acute inotropic effect is needed, what would you suggest? Increase levosimendan dose 
17% 
Add another inotrope 
83% 
If – after adequate reperfusion time – weaning from CPB cannot be easily 
accomplished in a patient pretreated with levosimendan (24 h before surgery or for a 
sufficient time and with a sufficient dose), what would do next? (multiple answers are 
allowed) 
IABP plus 
second inotrope 
Add a 
second 
inotrope 
Urge the surgeon to 
insert an IABP 
(if no contraindications) 
Proceed with weaning anyway and 
delay decisions for some h, 
awaiting the sometimes prolonged 
effect of levosimendan in the further 
course 
7/24 10/24 10/24 2/24 
Would you suggest combining levosimendan 
and phosphodiesterase inhibitors? 
83% NO 
Alternatively: Which inotrope do you recommend as a first-line agent, if additional 
inotropic support becomes necessary in a patient treated with levosimendan? (multiple 
answers are allowed) 
Dobutamine PDEI Epinephrine Dopamine Others 
14/24 4/24 8/24 2/24 1/24 
Would you suggest combining levosimendan and norepinephrine or vasopressin if 
vascular tone needs to be handled? 
100% YES 
If yes, which vasopressor approach do you suggest? The vast majority (23/24) suggests first-line norepinephrine and vasopressin only for severe 
hypotension 
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In a patient under beta blocker treatment requiring preoperative inotropic therapy, 
which drug would you suggest? (multiple answers are allowed) 
All the respondents (24/24) favour levosimendan. Phosphodiestherase inhibitors were suggested by 
4/24, while dobutamine and dopamine were not supported at all. 
Would you suggest the use of levosimendan plus IABP 
in a patient with overt LCOS? 
88% YES 
Would you urge the surgeon to implant an IABP in a patient preoperatively treated with 
a full dose of levosimendan, if post-induction TOE still shows severely depressed 
myocardial function? 
YES NO It depends (i.e. more likely in a patient with MV and/or TV 
regurgitation than in a single CABG case) 
50% 17% 33% 
  
3. Management of side effects 
In order to avoid arrhythmias during levosimendan infusion, what potassium target 
corridor would you suggest? 
Maintaining potassium levels of >4.0mmol/L Maintaining potassium levels of >3.5mmol/L 
92% 8% 
In order to avoid hypotension during levosimendan infusion, what would you suggest 
to do? (multiple answers are allowed) 
Optimising volume status 
before starting the drug 
administration 
Combining a vasoactive drug Combining a beta agonist 
drug 
19/24 16/24 0/24 
In order to avoid hypotension during levosimendan infusion, would you suggest to stop 
ACE inhibitor therapy before operation? 
63% YES 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
  
Table 3: Ongoing clinical trials on the use of levosimendan in cardiac surgery. 
 
Study indicators: title, acronym, 
NCT number and main 
investigator (when available)  
Patient population Patient 
number 
Levosimendan dose and 
time 
Comparator Endpoints 
LICORN (P110138)  
B. Cholley 
Patients with LVEF ≤40% 
undergoing CABG with or without 
valve replacement under CPB 
340  0.1 µg/kg/min infusion for 
24 h, started at the time of 
anaesthesia induction, 
without bolus application. 
Placebo Composite primary endpoint including use of inotropic agents 
beyond 24 h after end of study drug infusion, or need for 
postoperative mechanical assist devices (IABP or others), or 
impossibility to wean patients from them if they were already in 
use preoperatively, or the need for renal replacement therapy. 
Secondary endpoints comprise mortality at days 28 and 180, 
each item of the primary endpoint separately, and length of 
intensive care unit and hospital stays.  
Intracoronary administration of 
levosimendan in cardiac surgery 
patients, 
(NCT01500785) 
K. Järvelä 
Patients undergoing aortic valve 
and CABG surgery 
50 Intracoronary 12 µg/kg 
infusion, initiated at the 
induction of cardioplegia 
Placebo Primary endpoint of change in cardiac output 15 min after 
separation from CPB, compared to baseline. Secondary 
endpoints include change in LVEF between baseline and 5 min 
after sternal closure, and cTnT/CK-MB levels of first 
postoperative morning 
LEVO-CTS 
(NCT02025621) 
R. H. Mehta 
 
Patients undergoing CABG (LVEF 
≤25%) and/or mitral valve surgery 
(LVEF ≤35%) 
760 0.2 µg/kg/min infusion for 
1 h followed by 0.1 
µg/kg/min infusion for 23 
h, started before surgery. 
Placebo Two co-primary endpoints: 
• All-cause death at 30 days or use of mechanical assist device 
to day 5 
• All-cause death at 30 days, or perioperative non-fatal 
myocardial infarction to day 5, or need for renal dialysis to day 
30, or use of mechanical assist device to day 5 
Secondary endpoints:  
• Length of intensive care unit/ coronary care unit stay 
• Incidence of post-operative low cardiac output syndrome  
• Postoperative use of secondary inotrope  
Aristotle University of 
Thessaloniki, Greece  
K. Anastasiadis 
Patients with left ventricular 
dysfunction (LVEF ≤40%) 
scheduled for CABG 
32 0.1 µg/kg/min infusion for 
24 h before surgery 
Placebo Primary endpoint of assessment of left ventricular function by 
transthoracic echocardiography on 7th postoperative day. 
Secondary endpoints of cardiac index, tissue perfusion, and 
PCWP. 
HSR-LEVO 
(NCT00994825) 
G. Landoni 
High risk patients undergoing 
cardiac surgery with perioperative 
myocardial dysfunction 
1000 24-48 h infusion (varying 
doses) 
Placebo Primary endpoint of 30-day mortality  
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Figure legends  
 
Figure 1. Stroke volume (SVI) at the start of surgery (Base), 15 min after the end of 
cardiopulmonary bypass (post-CPB), at the end of the operation (End surgery), at arrival in 
the intensive care unit (T0), and 6 (T6), 12 (T12), 24 (T24), and 48 (T48) h later. 
Levosimendan (□) and Milrinone (▲). Data are mean ±standard deviation. *, Statistically 
significant difference between groups for P <0.05. (data from de Hert et al. [28]) 
 
Figure 2. PRISMA flow diagram [72] for search and inclusion of scientific information into 
systematic reviews applied to the search ((levosimendan OR Simdax) AND (surgery OR 
bypass OR valve OR CABG OR anest*)) updated March 27, 2014  
 
Figure 3. Cardiac troponin I concentrations (mean ±95% confidence intervals) in the 
levosimendan (□) and placebo (▲) groups before surgery (baseline), on arrival in the 
intensive care unit (0), and after 6, 24, and 48 h. (data from Tritapepe et al. [29]) 
 
Figure 4. Need for additional inotropic support in patients with LCOS after cardiac surgery in 
the study by Levin and colleagues [33], with treatment with levosimendan (white bars) and 
dobutamine (black bars). *, Statistically significant difference between groups for P <0.05. 
 
Figure 5. Weaning from cardiopulmonary bypass (CPB). First weaning attempt with 
levosimendan (white bars) and placebo (black bars). Epinephrine added to second weaning 
attempt. *, Weaning failure led to use of intra-aortic balloon pump (data from Eriksson et al. 
[27]). 
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Fig. 2 
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Fig. 3 
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Fig. 4 
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Fig. 5 
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Highlights 
 Review of cardiac and non-cardiac effects of intraoperative levosimendan 
treatment 
 A consensus on the use of levosimendan in the pre-operative settings is 
presented 
 Clear recommendations are proposed. 
 The ongoing studies on intraoperative levosimendan are described and 
commented 
